A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mmexp3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial

Trial Profile

A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mmexp3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2013

At a glance

  • Drugs Aldesleukin; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ESPRIT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jun 2012 Actual patient number changed from 4241 to 4169 as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Actual patient number changed from 4241 to 4169 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top